Big Data in Asia-Pacific - A Valuable Resource for Better Healthcare Decisions: Experiences and Lessons Learned in Japan

Bruce Crawford, MA, MPH
Senior Principal

Real-world data for real-world decisions

- RWD is being used to answer a plethora of health care questions in Japan
  - Burden of disease
  - Cost-effectiveness
  - Risk of disease / adverse effect
  - Understanding trial results
  - Treatment patterns
  - Safety evaluations
  - Trial simulations

- Methods within Japan have been improving
Putting trial results into context

- An increased risk of adverse events was found in clinical trials
- Little known about the underlying rate of events in the general disorder compared to non-disorder patients in Japan
- Conducted a database analysis to evaluate rate of events in the general disorder population and matched non-disorder patients
- Simulated trial results to understand what the rate would be in "trial like" patients in Japan
  - Following inclusion / exclusion criteria, a random selection of patients was generated to match the same gender distribution and same age (SD)

Retrospective DB analysis provided the underlying background rates of events in a Japanese population. By simulating a trial population, expected "natural" even rates could be compared with trial data.

Increasing chances of success

- Infection rates were well studied in the US / EU where trials were being designed
- Same protocol was to be used in Japan
  - Risk of failed trial if rates are different
- Using a retrospective database, key populations were identified where the risk of infection was higher
  - Results compared to Global protocol to evaluate appropriateness of joining Global trial

The evaluation of patient populations through retrospective DB allows the identification of key populations to be included in trials, ensuring enough events of interest to show differences
Evaluation of risks

Risk of CVD for Japanese RA patients

- MDV database utilized (April 2011 – March 2014)
- High CVD risk in Western patients but not well documented in Japan
- OA used as a comparator as inflammation is limited to the joints and not systemic like RA
- OA and RA share similar lifestyle risk factors associated with CVD
- Significant increase in CVD risk found in Japanese RA patients

<table>
<thead>
<tr>
<th>Table 2  Incidence rate ratios of cardiovascular disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA patients (N = 6658)</td>
</tr>
<tr>
<td>Events</td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td>CVD (total)</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
</tr>
<tr>
<td>Myocardial infarction</td>
</tr>
<tr>
<td>Angina pectoris</td>
</tr>
<tr>
<td>Ischemic stroke</td>
</tr>
<tr>
<td>Cerebral hemorrhage</td>
</tr>
<tr>
<td>Intracranial hemorrhage</td>
</tr>
<tr>
<td>Subarachnoid hemorrhage</td>
</tr>
</tbody>
</table>

* Adjusted by age and sex

Understanding current epidemiology and developing evidence

Using databases to evaluate event rates

Evaluate the incidence, time course and costs of VTE following major orthopedic surgery

Economic Impact of Venous Thromboembolism Following Major Orthopaedic Surgery in Japan

Shinro Takanai, MD, PhD, Masao Abe, MD, PhD, Bruce Crawford, MA, MPH, Satoyoshi Ichinose, MD, PhD, Takafumi Matsumune, MD, PhD, Hiroshi Miike, MD, PhD, Yosuke Niki, MD, PhD, Satoshi Tanaka, MD, PhD, Hiroshi Tashima, MD, PhD
Evaluation of treatment patterns and guideline adherence

- 33,325 patients with high cholesterol at high CV risk
- Treatment pattern evaluations in relation to Japan Atherosclerosis Society (JAS) guidelines – Statins 1st line therapy
- Only 45% of population treated with lipid-management therapy
- Guideline goal attainment low
- Patients with very high LDL-C levels not adequately treated

Fig. 1. LMT utilization by LDL-C levels. LDL-C, low-density lipoprotein cholesterol; LMT, lipid-modifying treatment.

Anti-epileptic treatments and cancer risk

Sequence symmetry analysis

A) Colorectal cancer

B) Lung cancer

C) Gastric cancer

D) Hematological malignancies


All Rights Reserved. Confidential and Proprietary.
Please contact us for more information

Bruce Crawford, MA, MPH
Senior Principal,
IMS Health Real-World
Evidence Solutions
bcrawford@jp.imshealth.com
+81 3 5425 9451

RWEinfo@imshealth.com
www.imshealth.com/rwe